Volver a la clasificación

ICU Medical, Inc. (ICUI)

NEUTRAL
HealthcareMedical Instruments & SuppliesUnited States

Fundamental

49

Precio

$183.10

Capitalización Bursátil

$4.55B

Parte 1 · Cuánto vale la empresa

Resumen

ICU Medical, Inc., together with its subsidiaries, develops, manufactures, and sells medical products used in infusion therapy, vascular access, and vital care applications worldwide. It offers Clave needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoLock closed system transfer devices and ChemoClaveTM for preparation and administration of hazardous drugs; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; ClearGuard, SwabCap, and SwabTip disinfection caps; and vascular access products. The company provides IV therapy and diluents, such as sodium chloride, dextrose, balanced electrolyte solutions, lactated ringer's, ringer's, mannitol, sodium chloride/dextrose, and sterile water; and irrigation solutions comprising sodium chloride, sterile water irrigation, physiologic solutions, ringer's irrigation, acetic acid irrigation, glycine irrigation, sorbitol-mannitol irrigation, flexible containers, and pour bottle options. It offers infusion pumps under the Plum 360 and Plum Duo brands; ambulatory and syringe infusion hardware products; IV mediation safety software, including ICU Medical MedNet, an enterprise-class medication management platform; LifeShield and PharmGuard medication infusion safety software; hemodynamic monitoring products; anesthesia systems and devices, breathing circuits, ventilation, respiratory, and specialty airway products; temperature management solutions; anesthesia/pain management trays and components; and professional services. The company's customers include acute care hospitals, wholesalers, ambulatory clinics, and alternate site facilities, such as outpatient clinics, home health care providers, and long-term care facilities. ICU Medical, Inc. was founded in 1984 and is based in San Clemente, California.

No editorial profile for this company yet

Direct competitors

Who this company fights with for the same customers

No editorial profile for this company yet

No competitor list for this company yet.

Balance y Liquidez

Ingresos

$2.16B

Últimos 12 meses (hasta 30/6/2026)

Beneficio Neto

$30M

Últimos 12 meses (hasta 30/6/2026)

Flujo de Caja Libre

$92M

Patrimonio Neto Total

$2.12B

Pasivo Total

$1.93B

Ratio de Liquidez

2.43

Cobertura de Intereses

0.87

Deuda/EBITDA

5.28

Beneficio Por Acción

Ingresos y Beneficio Neto

Flujo de Caja Libre

Desglose de Ingresos

Estado histórico

Márgenes en el tiempo

La deuda en el tiempo

Cuánto pesa la deuda

Cuadro de crecimiento

Crecimiento — Ingresos

Estimación de Valor Justo

General caseSobrevalorado

Valor Justo

$102.68

Precio Actual

$183.10

Margen de Seguridad

-78.3%

Rango de Valor Justo

$66.74 - $138.62

Métodos de Estimación

Analyst price target:$193.38
Discounted cash flow (DCF):$117.21
Earnings multiple (P/E):$22.75
Graham growth formula:$8.90
Earnings power value (EPV):$29.87
Justified P/B:Not enough data to compute it
Dividend discount (Gordon):Not enough data to compute it
P/FFO, funds from operations:Not enough data to compute it
Mid-cycle earnings:$234.96
Revenue multiple:Not enough data to compute it
Consenso de Analistas:Compra Fuerte (12B / 1H / 0S)
Última Sorpresa de Resultados:+21.43%

Métricas de Valoración

Ratio P/E

153.40

ROE

0.0%

Ratio P/B

2.12

P/FCF

29.87

Margen Bruto

39.1%

ROIC

1.6%

Radar de Rentabilidad

Value Creation (Economic Moat)

ROIC

1.6%

WACC

8.5%

ROIC − WACC

-6.8 pp

ROIC is below the cost of capital — the company is destroying value for every dollar invested.

Criterios de Análisis Fundamental

Superado (14)

  • Gross Margin 39.1%
  • P/FCF 29.87
  • P/B Ratio 2.12
  • Debt/Equity ratio
  • Positive Free Cash Flow
  • Current Ratio
  • Debt/EBITDA
  • Revenue Growth 5Y 11.9%
  • Analyst Consensus 92% Buy
  • Earnings Surprise avg 20.3%
  • Earnings Quality (OCF/NI) 7.86
  • Share Dilution 0.1%
  • Net Margin Trend 1.4% vs -1.6%
  • Piotroski F-Score 7/9

Fallido (12)

  • EPS shows upward trend
  • EPS CAGR -19.56%
  • Price CAGR 2.18%
  • ROIC 1.6%
  • Operating Margin 3.3%
  • CapEx intensity
  • Interest Coverage
  • Return on Tangible Assets
  • Low reliance on intangibles
  • Price below Graham Number
  • DCF valuation (Overvalued)
  • ROE 2.2%

No disponible (2)

  • Dividend Payout NaN%
  • PEG Ratio (need PE > 0 and growth > 0)

Piotroski F-Score

7/9

Solidez financiera fuerte

score
criteria

Calidad de los Beneficios

7.86

Alta calidad: beneficios respaldados por efectivo

Dilución de Acciones

0.1%

El número de acciones es estable

Gobernanza

Equipo Directivo

NombreCargoEdad
Mr. Vivek JainCEO & Chairman of the Board53
Mr. Daniel WoolsonPresident48
Mr. Brian Michael BonnellCFO & Treasurer51
Mr. Christian B. VoigtlanderChief Operating Officer57
Ms. Virginia Ruth SanzoneCorporate VP, General Counsel, Secretary & Compliance Officer50
Ben SousaChief Information Officer-
Olivia BarrallVice President of Human Resources-

Riesgo de Auditoría

5

Riesgo del Consejo

4

Riesgo de Compensación

4

Riesgo de Derechos del Accionista

5

Parte 2 · El precio y el momento de entrar

Esta parte no sirve para saber si la empresa vale: sirve para elegir cuándo comprarla, una vez que los fundamentales te han convencido. Dentro: análisis técnico, potencial, caídas históricas, exposición gamma.

Latest News

Recent headlines for ICUI, sourced from Markets Gazette.

No recent news for ICUI.